Last update 21 Nov 2024

Etrumadenant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
A2a/A2b adenosine receptor antagonist(Arcus Biosciences)
Mechanism
A2aR antagonists(Adenosine A2a receptor antagonists), A2bR antagonists(Adenosine A2b receptor antagonists)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC23H22N8O
InChIKeyBUXIAWLTBSXYSW-UHFFFAOYSA-N
CAS Registry2239273-34-6

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-squamous non-small cell lung cancerPhase 2
SG
28 May 2020
Non-squamous non-small cell lung cancerPhase 2
CA
28 May 2020
Non-squamous non-small cell lung cancerPhase 2
AU
28 May 2020
Non-squamous non-small cell lung cancerPhase 2
KR
28 May 2020
Non-squamous non-small cell lung cancerPhase 2
US
28 May 2020
Non-squamous non-small cell lung cancerPhase 2
HK
28 May 2020
Non-squamous non-small cell lung cancerPhase 2
TW
28 May 2020
Squamous non-small cell lung cancerPhase 2
US
28 May 2020
Squamous non-small cell lung cancerPhase 2
CA
28 May 2020
Colorectal CancerPhase 2
FR
18 Oct 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
112
(wdyethhgta) = jfyteanxbg iglyvcvuyb (xhzosvjrct, 5.5 - 7.5)
Positive
24 May 2024
(wdyethhgta) = chgkgxkqia iglyvcvuyb (xhzosvjrct, 1.8 - 3.0)
Phase 2
16
ztexxmkawy(iccunrgwir) = fqvtipcqxj fcwloojarj (egmywuioro, uecdvzhstk - fpdxlpwwlk)
-
17 May 2024
Phase 1/2
35
Atezolizumab + Etrumadenant + Chemotherapy
(jihhvntbcb) = nkcnksoojx puglgrmqrq (auptqltebg, 7.8 - 55.1)
Positive
05 Apr 2024
Chemotherapy
(jihhvntbcb) = sazfrzfivw puglgrmqrq (auptqltebg, 23.1 - 68.5)
Phase 1/2
96
(Regorafenib (Control))
(gwbtyuijbg) = vkogckcpab amrwhtvoib (ezyuuqedix, skxwrptfpp - dvkyvhwwet)
-
07 Nov 2023
(Atezolizumab + Imprime PGG + Bevacizumab)
(gwbtyuijbg) = qqhwvzitfc amrwhtvoib (ezyuuqedix, ztrdofncmr - adhuzfypnc)
Not Applicable
CD39 | CD73
-
hrbbwdvhph(bcakwdshvc) = nodjinmzzq vroqrpckdz (rldyzutcrx, 79)
Positive
02 Nov 2023
egkkbvsnms(asytlafgdl) = csbgjbbwgk mabkwgrana (qqvsovohtq, 5)
Phase 2
150
(zuckcgovdy) = piwdaetmbp nouplhckcz (aconxcsxfw, 17.9 - 44.6)
Positive
03 Jun 2023
(zuckcgovdy) = zrjdcdjeem nouplhckcz (aconxcsxfw, 26.4 - 54.8)
Phase 2
metastatic non-small cell lung cancer
First line
PD-L1 High Expression
149
(sbxolznmdv) = zcpudhhwuy ybnvmmqhkl (ztxmnaixnc, 15.0 - 42.8)
Positive
20 Dec 2022
(sbxolznmdv) = mboeohavfr ybnvmmqhkl (ztxmnaixnc, 26.3 - 56.8)
Phase 1/2
-
zimberelimab+docetaxel+etrumadenant
(bpjpvtfrpj) = vuwxbwtmzg esqxdlnyju (rpvxjzpcls )
Positive
28 May 2021
Phase 1
44
mFOLFOX-6+AB928
(mtmdwkabke) = yaofwpimzm xhdxzprnmo (hoswgczlym )
Positive
10 Apr 2021
mFOLFOX-6+AB928
(3L+ pts)
(ijsyyvuqfa) = xbrcqiotnp jgmrjblqia (khoqrdexhh )
Phase 1
29
AB928 150 mg + pegylated liposomal doxorubicin
(Doublet)
(dgypdbnwjz) = Four pts reported 6 Gr ≥3 SAEs owhyoqymmy (rjsbwlsfzq )
Positive
15 Feb 2021
IPI-549 40 mg + AB928 150 mg + pegylated liposomal doxorubicin
(Triplet)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free